What is the risk of NOT treating PSA-detected prostate cancer?

A new article in the May issue of Cancer Epidemiology, Biomarkers and Prevention appears to be a first attempt to project population-based probabilities of the occurrence of clinically significant prostate cancer among men who are diagnosed with prostate cancer but who receive no treatment. … READ MORE …

The continuing saga of the value of PSA velocity

An analysis of data from the Rotterdam and Göteborg subsets of men enrolled in the European Randomized Screening for Prostate Cancer (ERSPC) study suggests that PSA velocity is of little value in the identification of men who would benefit from a second biopsy after a first, negative biopsy. … READ MORE …